Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024 07:38 ET
|
Chemomab Therapeutics
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024 07:00 ET
|
Chemomab Therapeutics
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024 07:06 ET
|
Chemomab Therapeutics
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.
Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight
April 27, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 27, 2022 (GLOBE NEWSWIRE) -- Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight Primary Sclerosing...